Safety and Effects of Lactobacillus paracasei TISTR 2593 Supplementation on Improving Cholesterol Metabolism and Atherosclerosis-related parameters in Subjects with Hypercholesterolemia

Phase 1

Completed

• Conditions: Mild and Moderate Hypercholesterolemia; Lactobacillus paracasei; hypercholesterolemia; oxidative stress; inflammation; apolipoprotein E; monocyte chemoattractant protein-1; probiotic; clinical trial

• Registration Number: TCTR20220917002
• Lead Sponsor: Thailand Institute of Scientific and Technological Research (TISTR)

Brief Summary

Placebo group shows TC (231.48, 252.13, 267.70), TG (146.09, 157.96, 157.14) HDL-c (52.48, 58.65, 57.00), LDL-c (151.61, 161.87,163.00), MDA (0.071, 0.064, 0.078), TNF-alpha (11.541, 12.882,9.759), ApoE (0.783, 0.817, 0.806) (0, 45, 90 days). L. paracasei TISTR 2593 shows TC (233.50, 224.90, 277.75), TG (143.50, 153.60, 151.21) HDL-c (53.35, 56.75, 55.85), LDL-c (155.15, 137.40, 137.63), MDA (0.069, 0.045, 0.030), TNF-alpha (11.163, 9.656, 6.063), ApoE (0.751, 0.872, 0.887) (0, 45, 90 days).

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-02-21
• Study Start: 2022-09-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Subjects were eligible for the study both male and female (non-pregnant), aged 30 to 65 years, mild and modulate hypercholesterolemia, BMI between 19 and 30 kg/m2, no a vegan and vegetarian and no cholesterol and triglycerides lowering drug.

Exclusion Criteria

In the case of a previous cardiovascular event within the last 6 months, the presence of secondary dyslipaemias.

Study & Design

• Study Type: Interventional
• Study Design: Not specified